18 completed, 8 terminated, 6 active not recruiting, 2 recruiting. 35 Phase 2, 13 Phase 1, 1 Phase 3.
Follow Electrocardiogram: new trials by email Literature Review of Electrocardiogram trials Research Report on Electrocardiogram
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride - Malignant Digestive System Neoplasm | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 60 | 2026-04-30 | 2026-06-02 |
| Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas Sacituzumab Govitecan, EKG, Brain MRI - Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2025-06-09 | 2026-01-21 |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma Olaparib, ECG, CT CAP - Pancreatic Acinar Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2023-12-14 | 2026-08-14 |
| A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction Low calorie meal replacement plan, Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy, Transthoracic echocardiography - Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic | Phase 2 / Phase 3 | Completed | University of Leicester | 66 | 2023-12-05 | 2026-07-22 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide - GATA2, Immunodeficiency | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2023-11-29 | 2026-08-11 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer PRGN-2009, Pembrolizumab, EKG - Oropharyngeal Squamous Cell Carcinoma (SCC) | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 26 | 2023-11-07 | 2026-06-23 |
| Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction Iohexol measurement, Geranylgeranylacetone (GGA), Echocardiography - Heart Failure With Preserved Ejection Fraction | Phase 2 | Completed | Amsterdam UMC, location VUmc | 43 | 2023-04-26 | 2025-04-01 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| BMS-986253 in Myelodysplastic Syndromes Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-11-29 | 2025-09-30 |
| Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis Paclitaxel, Nilotinib, ECG - Gynecologic Cancer, Gynecologic Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2022-10-13 | 2026-06-25 |
| Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). Bintrafusp alfa/M7824, Ibuprofen, PET scan - Olfactory Neuroblastoma, Esthesioneuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2022-06-21 | 2025-08-08 |
| Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) Minnelide, ECG, CT/MRI - Adenosquamous Carcinoma of the Pancreas | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2022-03-07 | 2026-08-14 |
| Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19 Covidir injections, Quantitative PCR SARS-CoV-2, IgM and IgG dosage - COVID-19 | Phase 2 | Recruiting | Code Pharma | 130 | 2022-01-20 | 2024-10-02 |
| Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors Olaparib, Durvalumab, EKG - EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2021-07-07 | 2026-09-22 |
| Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease Ibrutinib, ECG, PFT's - Chronic GVHD | Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2021-05-10 | 2026-01-23 |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
| HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers PRGN-2009, M7824, EKG - HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 39 | 2020-08-11 | 2026-08-18 |
Showing 20 of 35. Sign in to see all of them.
Myelodysplastic Syndromes (4) · Hematologic Neoplasms (3) · Leukemia (3) · Lymphoma (3) · Colorectal Neoplasms (2) · Diabetes Mellitus, Type 2 (2) · Gastrointestinal Neoplasms (2) · Lung Neoplasms (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Prostatic Neoplasms (2) · Rectal Neoplasms (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Adenocarcinoma (1)
National Cancer Institute (NCI) (27) · Amsterdam UMC, location VUmc (1) · Children's Oncology Group (1) · Code Pharma (1) · Mayo Clinic (1) · Thomas Jefferson University (1) · University Hospital, Rouen (1) · University of Leicester (1) · University of Wisconsin, Madison (1)
United States (30) · Brazil (1) · Canada (1) · France (1) · Netherlands (1) · United Kingdom (1)
Charalampos Floudas, M.D. (3) · Anish Thomas, M.D. (2) · Chen Zhao, M.D. (2) · James Gulley, M.D. (2) · Najla El Jurdi, M.D. (2) · Adriaan Voors, MD, PhD (1) · Alain Mina, M.D. (1) · Andrew M Blakely, M.D. (1) · Chetan Jeurkar, DO (1) · Christopher J Melani, M.D. (1) · Danielle E Pregent-Arnold, M.D. (1) · Dimana Dimitrova, M.D. (1) · Gerry P McCann, MD (1) · James C Yang, M.D. (1)
PMID 42820295, PMID 30227893, PMID 32109194, PMID 32897402, PMID 33558725, PMID 33602696, PMID 34607348, PMID 35535581, PMID 37882668, PMID 39500789, PMID 39880434, PMID 40116923, PMID 40331908, PMID 40721826, PMID 42307670, PMID 42498485, PMID 42605066
1UL1TR002373-01 (1), 2015 (1), U10CA180886 (1)